Principles of antibacterial dosing in continuous renal replacement therapy
- PMID: 19487930
- DOI: 10.1097/CCM.0b013e3181aab3d0
Principles of antibacterial dosing in continuous renal replacement therapy
Abstract
Objectives: To outline the concepts involved in optimizing antibacterial dosing in critically ill patients with acute renal failure undergoing continuous renal replacement therapy (CRRT), provide a strategy for optimizing dosing, and summarize the data required to implement the strategy.
Data sources: MEDLINE search from February 1986 to 2008.
Data extraction and synthesis: Optimal dosing of antibacterials is dependent on achieving pharmacokinetic targets associated with maximal killing of bacteria and improved outcomes. The initial dose is dependent on the volume of distribution. Maintenance doses are dependent on clearance. Both should be adjusted according to the pharmacokinetic target associated with optimal bacterial killing, when known. The volume of distribution of some antibacterials is altered by critical illness or acute renal failure or both. Clearance by CRRT is dependent on the dose and mode of CRRT and the sieving or saturation coefficient of the drug. Both sieving and saturation coefficient are related to the plasma protein binding and thus may be altered in renal failure.
Conclusions: Appropriate dose calculation requires knowledge of the pharmacokinetic target and the usual minimum inhibitory concentration of the suspected organism in the patient's locality (or if unavailable, the break point for the organism), published pharmacokinetic data (volume of distribution, non-CRRT clearance) on critically ill patients receiving CRRT (which may differ substantially from noncritically ill patients or those without renal failure), the sieving or saturation coefficient of the relevant drug in critically ill patients, the dose and mode of CRRT being used, and the actual dose of CRRT that is delivered. This large number of variables results in considerable inter- and intrapatient heterogeneity in dose requirements. This article provides basic principles and relevant data to guide the clinician in prescribing individualized dosing regimes.
Similar articles
-
Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.Clin Pharmacol Ther. 1999 Jan;65(1):50-7. doi: 10.1016/S0009-9236(99)70121-9. Clin Pharmacol Ther. 1999. PMID: 9951430
-
Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.Clin Ther. 2005 May;27(5):599-608. doi: 10.1016/j.clinthera.2005.05.004. Clin Ther. 2005. PMID: 15978309
-
Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis.Pharmacotherapy. 2009 May;29(5):562-77. doi: 10.1592/phco.29.5.562. Pharmacotherapy. 2009. PMID: 19397464 Review.
-
[Pharmacokinetic principles and drug-dosing adjustments during continuous renal replacement therapies (CRRT)].G Ital Nefrol. 2006 May-Jun;23 Suppl 36:S127-38. G Ital Nefrol. 2006. PMID: 17068740 Review. Italian.
-
Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study.ASAIO J. 2006 Jul-Aug;52(4):398-403. doi: 10.1097/0.1mat.0000225268.28044.ae. ASAIO J. 2006. PMID: 16883119
Cited by
-
Optimization of antimicrobial treatment in sepsis.Rev Esp Quimioter. 2022 Oct;35 Suppl 3(Suppl 3):30-33. doi: 10.37201/req/s03.07.2022. Epub 2022 Oct 24. Rev Esp Quimioter. 2022. PMID: 36285854 Free PMC article. Review.
-
Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration.Antimicrob Agents Chemother. 2011 Dec;55(12):5804-12. doi: 10.1128/AAC.01758-10. Epub 2011 Sep 12. Antimicrob Agents Chemother. 2011. PMID: 21911561 Free PMC article.
-
The Clearance of Midazolam and Metabolites during Continuous Renal Replacement Therapy in Critically Ill Patients with COVID-19.Blood Purif. 2024;53(2):107-113. doi: 10.1159/000534538. Epub 2023 Nov 3. Blood Purif. 2024. PMID: 37926072 Free PMC article.
-
Edoxaban pharmacokinetics during in vitro continuous renal replacement therapy.BMC Nephrol. 2024 Oct 10;25(1):341. doi: 10.1186/s12882-024-03777-7. BMC Nephrol. 2024. PMID: 39390394 Free PMC article.
-
Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.Antimicrob Agents Chemother. 2011 Dec;55(12):5868-73. doi: 10.1128/AAC.00424-11. Epub 2011 Sep 19. Antimicrob Agents Chemother. 2011. PMID: 21930888 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical